Malaria vaccine-related adverse events among children under 5 in sub-Saharan Africa: systematic review and meta-analysis protocol
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    The R21/Matrix-M vaccine is a new 2nd malaria vaccine recommended by the World Health Organization (WHO) for the prevention of plasmodium falciparum malaria in children
    • Professor Dr Pranab Kumar Bhattacharya, Retired Professor and Head of Pathology department Retired from Calcutta School of Tropical Medicine 108 Chittaranjan Avenue Kolkata 73West Bengal India

    Dear Editor
    The R21/Matrix-M vaccine is a new vaccine recommended by the World Health Organization (WHO) for the prevention of malaria in children below age 5 years , in pregnant women, in travellers and individuals with HIV and AIDS (1) . It is the second malaria vaccine recommended by WHO, following the first RTS,S/AS01 vaccine, which received a WHO recommendation in 2021 (1) . The R21 vaccine is shown to be safe and effective in preventing malaria in children and, when implemented broadly, is expected to have high public health impact (1) in the rainy season.
    The R21/Matrix-M vaccine was developed by the University of Oxford and is a low-dose vaccine that can be manufactured at mass scale and modest cost, enabling as many as hundreds of millions of doses to be supplied to African countries which are suffering a significant malaria burden (3) . The vaccine targets the first form of the malaria parasite (the plasmodium sporozoite) to enter the body after a person is bitten by an infected mosquito (2)
    The updated WHO malaria vaccine recommendation is informed by evidence from an ongoing R21 vaccine clinical trial and other studies, which showed high efficacy when given just before the high transmission season. In areas with highly seasonal malaria transmission (where malaria transmission is largely limited to 4 or 5 months per year as it is in Ghana and Nigeria), the R21 vaccine was shown to reduce symptomatic cases of malaria by 75%-77% during the 12...

    Show More
    Conflict of Interest:
    None declared.